Maribavir/Yitazhi drug interaction cases

Maribavir (Maribavir) is a Cytomegalovirus (CMV) pUL97 kinase inhibitor. Its drug metabolism characteristics determine that it has a clear risk of drug interactions in clinical practice, especially for some drugs metabolized by CYP3A4, P-gp or OATP pathways. In transplant patients, since multiple immunosuppressives, anti-infective drugs, anticoagulants, etc. are often combined, careful evaluation of drug interactions is critical when using maribavivir.

Data show that maribavivir is a strong inhibitor of CYP3A and P-gp. It also has varying degrees of effects on transporters such as BCRP and OATP1B1. Therefore, the plasma concentrations of many types of drugs may increase. For example, common immunosuppressants such as tacrolimus, cyclosporine, sirolimus , etc. are metabolized by CYP3A4. When patients use maribavivir concurrently, the concentration of immunosuppressants may increase significantly, which may lead to liver and kidney toxicity, blood pressure fluctuations, or neurological adverse reactions if the dose is not adjusted. Therefore, professional guidelines from many countries recommend reducing the dose of immunosuppressants during the initial period of maribavivir combination use and monitoring drug blood concentrations daily to ensure that they are within a safe range.

Another type of highly relevant drugs are anti-epileptic drugs, such as phenytoin, carbamazepine, etc., which are potent inducers of CYP3A4 which will reduce the plasma concentration of maribavivir, resulting in a weakened anti-CMV effect. Therefore, it is recommended that such strong inducers be avoided in combination with maribavivir. If patients must take antiepileptic drugs, an alternative with less potent CYP effects, such as levetiracetam, should be chosen.

In terms of antiviral drugs, traditional CMV treatment drugs such as ganciclovir and valganciclovir have an antagonistic mechanism with maribavir and should not be used in combination. This is because the activation pathways of pUL97 kinase and ganciclovir are directly cross-blocked, and combined treatment not only fails to enhance the efficacy, but may reduce the overall antiviral effect. Therefore, conventional CMV drugs must be explicitly discontinued before treatment with maribabavir.

Reference materials:https://www.livtencity.com/